Atticus Wealth Management LLC Grows Stake in Pfizer Inc. (NYSE:PFE)

Atticus Wealth Management LLC grew its holdings in Pfizer Inc. (NYSE:PFEGet Rating) by 40.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 7,968 shares of the biopharmaceutical company’s stock after buying an additional 2,292 shares during the quarter. Atticus Wealth Management LLC’s holdings in Pfizer were worth $418,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Baltimore Washington Financial Advisors Inc. purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $290,000. Rinkey Investments purchased a new position in Pfizer during the fourth quarter valued at $32,000. Worth Asset Management LLC purchased a new position in Pfizer during the first quarter valued at $29,000. Bivin & Associates Inc. purchased a new position in Pfizer during the fourth quarter valued at $37,000. Finally, Stuart Chaussee & Associates Inc. raised its stake in Pfizer by 108.3% during the first quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 325 shares during the last quarter. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. set a $57.00 price objective on Pfizer in a research note on Tuesday, June 28th. Morgan Stanley lowered their price objective on Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a research note on Friday, July 8th. The Goldman Sachs Group set a $50.00 target price on Pfizer in a report on Thursday, September 1st. UBS Group set a $59.00 target price on Pfizer in a report on Thursday, September 1st. Finally, SVB Leerink reduced their target price on Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a report on Friday, July 29th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $57.00.

Pfizer Stock Performance

NYSE:PFE opened at $44.57 on Friday. The stock has a 50-day simple moving average of $48.40 and a two-hundred day simple moving average of $50.33. Pfizer Inc. has a 52-week low of $40.94 and a 52-week high of $61.71. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.20 and a current ratio of 1.42. The firm has a market capitalization of $250.14 billion, a PE ratio of 8.72, a P/E/G ratio of 0.54 and a beta of 0.70.

Pfizer (NYSE:PFEGet Rating) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.95 by $0.09. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. The business had revenue of $27.74 billion for the quarter, compared to the consensus estimate of $26.20 billion. During the same period in the previous year, the business earned $1.07 earnings per share. The business’s revenue was up 46.8% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 6.54 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 5th. Stockholders of record on Friday, November 4th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 3.59%. Pfizer’s payout ratio is 31.31%.

About Pfizer

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.